Tag: the war on (some) drugs

CBD Could Effectively Treat Common Vaginal Infections, Study Concludes

Newly published research on cannabidiol (CBD) suggests that the popular marijuana component could be a promising treatment for a common type of vaginal infection.

The report focuses on the bacterium Gardnerella vaginalis, which is found naturally in the vagina but can also cause vaginosis when out of balance with other microbes. In laboratory tests, CBD demonstrated antibacterial and antioxidant effects that weakened G. vaginalis and eliminated communities of the bacteria known as biofilms.

“Our study shows that CBD exhibits antibacterial and antibiofilm activities against G. vaginalis clinical isolates,” the new paper says, “and is thus a potential drug for the treatment of vaginosis caused by this bacterium.”

The article was published this month in a special issue of the journal Antibiotics dedicated to “Antimicrobial and Antibiofilm Activity by Natural Compounds.” It was authored by a four-person team from The Hebrew University of Jerusalem and Hadassah-Hebrew University Medical Center, also in Jerusalem, Israel.

Keep reading

Wisconsin Governor Puts Marijuana Legalization In Budget Request, Along With Provisions To Regulate Hemp-Derived THC

The governor of Wisconsin has once again included a proposal to legalize marijuana in his biennial budget request.

“Legalize, regulate, and tax the sale of marijuana for recreational use, much like Wisconsin already does with alcohol,” a budget brief that the office of Gov. Tony Evers (D) released on Tuesday says, adding that it will result in “$58.1 million in revenue in fiscal year 2026-27 and growing amounts in future years.”

Under current Wisconsin law, cannabis is illegal for both recreational and medical purposes.

The governor’s proposal would additionally “create a process for individuals serving sentences or previously convicted of marijuana-related crimes to have an opportunity to repeal or reduce their sentences for nonviolent minor offenses.”

“The Governor further recommends the imposition of a 15 percent wholesale excise tax and a 10 percent retail excise tax on the sale of marijuana for recreational use by department-issued permit holders,” it says.

Identical bills to facilitate the budget requests have been filed in both the Senate and Assembly.

In addition to legalizing cannabis for adult use, Evers is proposing to include delta-8, delta-10 THC and other intoxicating hemp-derived cannabinoids in the definition of marijuana to “ensure their production, processing and sale is regulated and not available to individuals under 21.”

Further, the governor is calling for the the Department of Revenue the enter into agreements with tribal territories “for the refund to tribes of marijuana excise taxes estimated to be collected from sales on tribal lands,” similar to current policy with tobacco products.

The companion bills that were filed in tandem with the governor’s budget request stipulate that all revenue collected from the proposed cannabis taxes will be deposited into the state general fund.

Keep reading

Idaho Lawmakers Send Bill Creating A Mandatory Minimum Fine For Marijuana Possession To Governor’s Desk

The Idaho Senate voted 27-8 on Tuesday to pass a bill creating a mandatory minimum fine of $300 for simple marijuana possession.

Passing the Senate was the final legislative hurdle for the bill. The Idaho House of Representatives already voted 54-14 to pass the bill January 21.

House Bill 7 next heads to Gov. Brad Little’s (R) desk for final consideration. Once it reaches his desk, Little will have three options. He can sign it into law, he can allow it to become law without his signature or he can veto it.

If the bill becomes law it would take effect July 1.

House Bill 7 was co-sponsored by Sen. Brandon Shippy, R-New Plymouth. If passed into law, it would create a mandatory minimum fine of $300 for anybody 18 and over convicted of possessing less than 3 ounces of marijuana—in addition to any other penalties allowed by law.

Supporters of the bill said it is a way to be tough on marijuana and differentiate Idaho from its neighboring states.

Most of Idaho’s neighboring states allow for the recreational or medical use of cannabis. Oregon, Washington, Nevada and Montana allow the recreational sale and possession of cannabis, while Utah offers medical cannabis.

“Not long ago, marijuana was illegal in all 50 states,” Shippy said. “In not one state where marijuana is legalized has that state become a better, safer or more wealthy place to live and raise a family.”

Some opponents of the bill argued against creating a mandatory minimum fine, saying it removes discretion that judges and prosecutors exercise on a case-by-case basis.

The bill is similar to a failed bill from last year, House Bill 606, which would have created a mandatory minimum fine of $420 for marijuana possession.

Keep reading

Sell Flavored Tobacco in Massachusetts, Go To Jail

In 2022, I wrote an article for Reason predicting that it was only a matter of time before selling flavored tobacco products landed an American behind bars. Almost three years later, that day has arrived in Massachusetts. According to a press release from the Middlesex district attorney and the Department of Revenue, the owner of a Marlborough vape shop has pleaded guilty to three counts of attempted tax evasion arising from the sale of e-cigarettes brought in from across state borders. He was sentenced to serve six months in the House of Correction and five years probation.

In 2020, Massachusetts became the first state to implement a comprehensive ban on all flavored tobacco products, including menthol cigarettes and flavored e-cigarettes. Violation of the flavor ban is only a misdemeanor, but since flavored tobacco products are sold on the illicit market, sellers simultaneously violate state tax law. This brings much harsher penalties into play. In Massachusetts, evading taxes on tobacco products is a felony punishable by up to five years in prison.

Criminal justice reformers have warned for years that flavor bans would encourage illicit markets, creating felony crimes in the process. For example, a 2021 coalition letter signed by groups such as the American Civil Liberties Union and National Association of Criminal Defense Lawyers warned that a federal menthol ban would create “a massive law enforcement problem for states, counties, and cities since all states treat unlicensed sale of tobacco products as a crime—usually as a felony punishable by imprisonment.”

This is a prescient description of how the comprehensive flavor ban in Massachusetts is working out. The latest annual report from the state’s Multi-Agency Illegal Tobacco Task Force (published in February 2024) notes: “Field personnel are routinely encountering or seizing untaxed menthol cigarettes, originally purchased in other states, and flavored ENDS [electronic nicotine delivery systems] products and cigars purchased from unlicensed distributors operating both within and outside the Commonwealth. Without providing too much detail about the processes and methods of Task Force enforcement strategies, smugglers are developing more sophisticated smuggling operations to counter the Task Force’s targeted investigations.” 

These annual reports document law enforcement activity directly related to the flavor ban. Massachusetts has seized so much contraband tobacco and so many e-cigarettes that the state struggles to find the capacity to store it all. There are many instances of individuals arrested for possessing allegedly commercial quantities of menthol cigarettes or flavored e-cigarettes, with some of these cases referred for prosecution.

The Marlborough case is one of the first, if not the first, to resolve with a guilty plea and criminal sentence. The defendant is 62-year-old Ashraf Youssef, who owned AAA Smoke and Vape Shop. According to prosecutors, he “routinely” purchased e-cigarettes from out-of-state distributors between 2020 and 2022, evading $467,000 in excise taxes. In high-tax states like Massachusetts, there are obviously financial reasons to smuggle products from other jurisdictions, but the prohibition on flavored products offers additional motivation.

The Massachusetts flavor ban took effect in 2020, and minutes from a 2022 Marlborough Board of Health meeting note multiple instances of Youssef’s shop selling flavored products. In December of 2021, for example, a “Tobacco Control Manager stopped at the establishment, witnessed the sale of flavored tobacco products, and found 300 disposable flavored vapes.” And in March of 2022, “The Marlborough Police Department was sent to investigate suspicious activity in the parking lot of AAA Smoke & Vape. They determined the business has a car parked outside where patrons can walk up & purchase flavored vape products for cash.”

Keep reading

Psychedelic use linked to reduced distress, increased social engagement in autistic adults

A recent study has found that some autistic adults report lasting improvements in their mental health and social lives after using psychedelic drugs. The research, published in the journal Psychopharmacology, revealed that a significant number of autistic individuals attributed reductions in distress and social anxiety, along with increased social engagement, to a single, impactful psychedelic experience. However, the study also highlighted that a minority of participants experienced negative effects, emphasizing the need for caution and further research in this area.

There is a growing interest in the potential of psychedelic drugs to treat various mental health conditions, such as depression and post-traumatic stress disorder, in the general population. Autism spectrum disorder, a developmental condition characterized by challenges in social interaction and communication, as well as repetitive behaviors, often co-occurs with mental health difficulties. Autistic individuals are known to experience higher rates of anxiety, depression, and loneliness, and often report a lower quality of life compared to non-autistic people.

While psychedelics are being explored as therapies for mental health in broader populations, there is very little scientific understanding of how these substances affect autistic individuals specifically. Some anecdotal accounts suggested that psychedelics might be helpful for autistic people, potentially by improving their understanding of themselves and their emotions, but rigorous research was lacking. The new study aimed to investigate the experiences of autistic adults who have used psychedelics and to understand if they perceived any changes in their mental health and social abilities as a result.

To conduct their investigation, the researchers used an online survey to gather information from adults who identified as autistic. Participants were recruited through advertisements on social media platforms, online forums related to psychedelics and autism, and by collaborating with an organization called the Autistic Psychedelic Community. The advertisements were carefully worded to encourage participation from individuals with both positive and negative psychedelic experiences. To be included in the study, participants had to be at least 18 years old, fluent in English, and either have a formal diagnosis of autism from a healthcare professional or self-identify as autistic. They also needed to have used a psychedelic substance at least once in their lives.

A total of 284 people completed the survey. For their analysis, the researchers focused on 233 participants who reported that their most ‘impactful’ psychedelic experience involved a classic psychedelic drug, such as lysergic acid diethylamide (LSD) or psilocybin (the active compound in magic mushrooms). The other participants who were excluded from the main analysis had reported that their most impactful experience was with substances like MDMA, cannabis, or ketamine.

Keep reading

Florida Bill Would Let People With Opioid Use Disorder Qualify For Medical Marijuana

A newly introduced bill in the Florida Senate would expand eligibility for the state’s medical marijuana program by adding as a qualifying condition “an addiction to or dependence on an opioid drug.”

The legislation, SB 778, was filed Monday by Sen. Carlos Guillermo Smith (D). If enacted, it would take effect on July 1 of this year.

Current qualifying conditions for medical marijuana in Florida include cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn’s disease, Parkinson’s disease, multiple sclerosis, terminal conditions and chronic pain caused by a qualifying condition, according regulators at the state’s Office of Medical Marijuana Use (OMMU).

The new bill has not yet been referred to a committee, according to the state Senate website.

Smith has in the past also filed legislation to legalize cannabis for adults, and last year he criticized Gov. Ron DeSantis (R) for spending the state’s opioid settlement funds on advertisements opposing Amendment 3, an industry-funded ballot measure that would have legalized adult-use cannabis in the state.

“Thousands of Floridians have died from opioid overdoses. ZERO Floridians have died from marijuana overdose,” he said on social media last October. “Yet DeSantis is spending MILLIONS of Florida’s opioid settlement money meant to fight the opioid crisis on his prohibitionist anti-freedom, anti-marijuana campaign.”

Keep reading

Federal Court Rejects Washington Doctor’s Effort To Legally Access Psilocybin For End-Of-Life Patient Care

A federal appellate court has rejected the latest effort by a Washington State doctor who is seeking to legally use psilocybin to treat cancer patients in end-of-life care, ruling that the Drug Enforcement Administration (DEA) provided a reasonable explanation in denying the doctor’s request.

In an opinion filed on Thursday, a three-judge panel of the U.S. Court of Appeals for the Ninth Circuit rejected arguments from lawyers for Dr. Sunil Aggarwal and his clinic, the Advanced Integrated Medical Science (AIMS) Institute that DEA’s denial of Aggarwal’s efforts was arbitrary and capricious

“DEA’s decision to deny AIMS’s request was neither arbitrary nor capricious,” the court concluded. “We therefore deny AIMS’s petition for review of the DEA’s decision.”

Aggarwal and AIMS have been working since at least 2020 to find a way to legally obtain psilocybin for patients in palliative care, initially seeking to win permission from regulators under state and federal right-to-try laws.

When DEA rebuffed that request, Aggarwal sued. In early 2022, a federal appellate panel dismissed the lawsuit, opining that the court lacked jurisdiction because DEA’s rejection of Aggarwal’s administrative request didn’t constitute a reviewable agency action.

The latest Ninth Circuit ruling results from Aggarwal’s responses to that ruling. In February 2022, the doctor filed a formal petition with DEA to reschedule psilocybin from Schedule I to Schedule II under the federal Controlled Substances Act (CSA)—the denial of which is a reviewable action. He also applied for a regulatory waiver to obtain psilocybin.

DEA denied Aggarwal’s petition in September 2022 and rejected the waiver request the next month. The doctor’s Ninth Circuit case challenged both decisions.

“Following the dismissal of its earlier petition, AIMS returned to DEA with a concrete request. AIMS asked EA to exempt Dr. Aggarwal from registration under the CSA, either by finding that Dr. Aggarwal’s proposed use of psilocybin was not covered by the CSA’s registration requirement or by waiving the registration requirement,” Judge Marsha Berzon, a Clinton appointee, wrote for the court in Thursday’s opinion. “DEA declined to take action, and AIMS again petitioned for review. Because DEA’s response was neither arbitrary nor capricious, we deny AIMS’s petition for review.”

Keep reading

RFK Jr. Says Marijuana Can Have ‘Catastrophic Impacts’ On Consumers, But State-Level Legalization Can Spur Research On Its Harms And Benefits

Fresh off his Senate confirmation vote to become the secretary of the U.S. Department of Health and Human Services, Robert F. Kennedy Jr. said on Thursday that he is “worried about” the normalization of high-potency marijuana and that he feels its use can have “really catastrophic impacts” on people, but that state-level legalization can facilitate research into its harms and benefits.

Kennedy, who was vocal about his support for marijuana legalization when he was running for president—as well as during his time on the Trump transition team—has been notably silent on cannabis policy issues over recent months as he worked to win over senators to secure confirmation for the country’s top health role.

Now, during his first major media interview since receiving that final vote to secure the cabinet position earlier in the day, Kennedy told Fox News’s Laura Ingraham that he believes cannabis does hold serious harm potential.

The HHS secretary, who personally struggled with drug addiction during his youth, was asked about his cannabis policy position and noted that he’s been in recovery for over 40 years and attends daily 12-step meetings.

“I hear stories all the time of the impacts of marijuana on people—and the really catastrophic impacts on them,” he said.

However, Kennedy said “that worry also has to be balanced [with] the impacts that we’ve had before” as it relates to criminalization.

“Twenty-five states [have] now legalized marijuana, but we had about a third of our prison population that was in jail because of marijuana offenses,” he said. “That’s something we don’t want either.”

“Because of the legalization of recreational marijuana in 25 states, we have now a capacity to really study it and to compare it to states,” he said. “We need to do studies. We need to figure it out, and then we need to we need to implement policies to address” any health concerns.

Of course, HHS has already completed a comprehensive scientific study into cannabis that led the agency under the Biden administration to recommend moving marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA).

The new comments come on the same day that Sen. Pete Ricketts (R-NE) said he received a commitment from Kennedy to “follow the science on the harms of marijuana.”

Ricketts had already disclosed last week that he spoke to Kennedy about the the “importance” of “preventing the expansion of marijuana.” Now he says “RFK committed to me that he would follow the science on the harms of marijuana.”

Keep reading

Montana GOP Senator’s Bill Would Require People To Register And Pay A $200 Annual Fee To Use Recreational Marijuana

Marijuana reform advocates are sounding the alarm after a Montana GOP senator filed a bill that would require adult-use cannabis consumers to register and pay a $200 annual fee to participate in the legal program that voters approved in 2020.

Sen. Greg Hertz (R) introduced the legislation, SB 255, last week. It would create a registration system similar to what’s in place for medical cannabis in many states—except that this would be for adults in a recreational market, with a significantly higher annual fee.

Adults would need to pay the $200 fee to obtain a cannabis card from the state Cannabis Control Division (CCD). Participants would need to pay that fee each year for renewal under the proposal.

Upon applying for the card, there would be a 60-day period where adults could access marijuana from licensed retailers. But if they don’t pay the fee by the end of that window, the division “shall cancel the temporary marijuana identification card.”

“This is an outrageous attempt to gut the will of the people and re-criminalize cannabis for most Montanans. Voters legalized cannabis for all adults 21 and older,” Karen O’Keefe, director of state policies at the Marijuana Policy Project (MPP), told Marijuana Moment on Thursday.

“No other adult-use state forces cannabis consumers to enroll in a state registry, and the people’s initiative explicitly prohibits this surveillance and government overreach,” she said. “Re-criminalizing cannabis for anyone who does not pay $200 per year to register with the state is an affront to Montana voters who made their voices clear when they passed Initiative I-190.”

The text of the bill states that a “marijuana cardholder shall keep the individual’s marijuana identification card in the individual’s immediate possession at all times. The marijuana identification card and a valid photo identification must be displayed on demand of a law enforcement officer, justice of the peace, or city or municipal judge.”

Keep reading

Trump asked to shut down NYC ‘injection sites’ where drug addicts consume with impunity

The Trump administration is being urged to shut down two controversial city-approved “safe” injection sites — where drug addicts can use illegal drugs like meth, heroin and cocaine under supervision.

Republican US Rep. Nicole Malliotakis is asking Trump to step in to close the government-sponsored centers in East Harlem and Washington Heights, saying they violate federal law.

“These sites not only enable but also perpetuate illegal drug use,” Malliotakis wrote in a Feb. 11 letter to Attorney General Pam Bondi, a copy of which was obtained by The Post.

The Staten Island congresswoman cited a Third Circuit of Appeals ruling in Philadelphia that concluded it was a federal crime to “open a supervised injection site or ‘consumption room’ for illegal drug use.”

Keep reading